BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector

Reuters

Dec 01, 2025

BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application <a href="https://laohu8.com/S/SNDA">$(SNDA)$</a> Of Furoscix Readyflow™ Autoinjector

Dec 1 (Reuters) - MannKind Corp MNKD.O:

MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF FUROSCIX READYFLOW™ AUTOINJECTOR FOR THE TREATMENT OF EDEMA IN ADULTS WITH CHRONIC HEART FAILURE OR CHRONIC KIDNEY DISEASE
MANNKIND CORP - PDUFA TARGET ACTION DATE SET FOR JULY 26, 2026

Source text: ID:nGNX9rqQK6

Further company coverage: MNKD.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588206877"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588206877\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588206877?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588206877","market":"fut","top_or_hot":-1,"title":"BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application <a href=\"https://laohu8.com/S/SNDA\">$(SNDA)$</a> Of Furoscix Readyflow™ Autoinjector </title></head><body><p><span>Dec 1 (Reuters)</span><span> - </span>MannKind Corp <span>MNKD.O</span>:</p><ul><li><p>MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF FUROSCIX READYFLOW™ AUTOINJECTOR FOR THE TREATMENT OF EDEMA IN ADULTS WITH CHRONIC HEART FAILURE OR CHRONIC KIDNEY DISEASE</p></li><li><p>MANNKIND CORP - PDUFA TARGET ACTION DATE SET FOR JULY 26, 2026</p></li></ul><p>Source text: <span>ID:nGNX9rqQK6</span></p><p>Further company coverage: <span>MNKD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-01 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application <a href=\"https://laohu8.com/S/SNDA\">$(SNDA)$</a> Of Furoscix Readyflow™ Autoinjector </title></head><body><p><span>Dec 1 (Reuters)</span><span> - </span>MannKind Corp <span>MNKD.O</span>:</p><ul><li><p>MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF FUROSCIX READYFLOW™ AUTOINJECTOR FOR THE TREATMENT OF EDEMA IN ADULTS WITH CHRONIC HEART FAILURE OR CHRONIC KIDNEY DISEASE</p></li><li><p>MANNKIND CORP - PDUFA TARGET ACTION DATE SET FOR JULY 26, 2026</p></li></ul><p>Source text: <span>ID:nGNX9rqQK6</span></p><p>Further company coverage: <span>MNKD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA1D7KG6:1","article_id":"2588206877","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588206877","pubTimestamp":1764594352,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow Autoinjector Dec 1 (Reuters) - MannKind Corp MNKD.O:MANNKIND ANNOUNCES U.S. FDA ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4139":"生物科技","MNKD":"曼恩凯德生物医疗"},"translate_title":"简报-Mannkind宣布美国FDA接受其Furoscix Readyflow的补充新药申请(SNDA)审查™自动注射器","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":0.9},"content_text":"BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application $(SNDA)$ Of Furoscix Readyflow™ Autoinjector Dec 1 (Reuters) - MannKind Corp MNKD.O:MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) OF FUROSCIX READYFLOW™ AUTOINJECTOR FOR THE TREATMENT OF EDEMA IN ADULTS WITH CHRONIC HEART FAILURE OR CHRONIC KIDNEY DISEASEMANNKIND CORP - PDUFA TARGET ACTION DATE SET FOR JULY 26, 2026Source text: ID:nGNX9rqQK6Further company coverage: MNKD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}